<DOC>
	<DOCNO>NCT00156091</DOCNO>
	<brief_summary>Schizophrenia brain disease . The primary feature schizophrenia characterize Positive symptom ( symptom , inability think clearly , distinguish reality fantasy i.e. , hear voice ) Negative symptom ( reduction absence normal behavior emotion , i.e. , unable manage emotion , make decision relate others ) . Other symptom include reduced ability recall learn new information , difficulty problem solve , maintain productive employment . The symptom schizophrenia may due imbalance chemical brain , primarily dopamine serotonin , enable brain cell communicate . The clinical development asenapine , described 2007 IDB appear antipsychotic activity superior symptomatic control compare placebo improve safety profile compare currently available neuroleptic . Its fast dissolving formulation may add treatment compliance . While various titration schedule use previous study , dose increase 5 mg BID 10 mg BID well tolerate . Therefore , exploration large group subject acute exacerbation schizophrenia use asenapine flexible dosing design ( 5 10 mg BID ) mimic actual clinical practice long-term 52-week extension trial .</brief_summary>
	<brief_title>Long-Term Efficacy Safety Asenapine Using Olanzapine Positive Control ( 41512 ) ( COMPLETED ) ( P05784 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Completed shortterm trial ( 041021 021022 ) Continued meet demographic procedural inclusion criterion shortterm trial upon entry longterm extension trial Sign write informed consent 041512 trial . Demonstrated acceptable degree compliance trial medication shortterm trial opinion investigator CGIS score great equal 6 ( severely psychotic ) Occurrence ( ) AE clinically significant finding would prohibit continuation Met exclusion criterion regard medical/psychiatric status list shortterm trial ( 041021 041022 ) Met exclusion criterion medication status shortterm trial except antidepressant mood stabilizer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>